Skip to Content
Merck
All Photos(3)

Key Documents

View All Documentation

V900323

Sigma-Aldrich

Hydroxyurea

Vetec™, reagent grade, ≥98%

Synonym(s):

Hydroxycarbamide

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Linear Formula:
NH2CONHOH
CAS Number:
127-07-1
Molecular Weight:
76.05
Beilstein:
1741548
EC Number:
204-821-7
MDL number:
MFCD00007943
UNSPSC Code:
12352200
PubChem Substance ID:
329829741

grade

reagent grade

product line

Vetec™

Assay

≥98%

storage temp.

2-8°C

SMILES string

NC(=O)NO

InChI

1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

InChI key

VSNHCAURESNICA-UHFFFAOYSA-N

Gene Information

human ... RRM1(6240) , RRM2(6241) , RRM2B(50484)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H340,H361

Precautionary Statements

P201 - P281 - P308 + P313

Hazard Classifications

Muta. 1B - Repr. 2

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
WXBB0556
SLBC2132V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Deepa Manwani et al.
Blood, 122(24), 3892-3898 (2013-09-21)
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted
Guido Finazzi et al.
British journal of haematology, 161(5), 688-694 (2013-04-12)
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia
Winfred C Wang et al.
Pediatrics, 132(4), 677-683 (2013-09-04)
In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care
Suchitra Natarajan et al.
Neoplasia (New York, N.Y.), 15(3), 263-280 (2013-03-13)
The non-histone chromatin binding protein high mobility group AT-hook 2 (HMGA2) is expressed in stem cells and many cancer cells, including tumor initiating cells, but not translated in normal human somatic cells. The presence of HMGA2 is correlated with advanced
A Tefferi et al.
Leukemia, 28(12), 2300-2303 (2014-05-06)
The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service